Relations Of The Level Of Plasma PAI-1 With Urine Micro-albumin In Type 2 Diabetes Mellitus

ObjectiveDiabetic vascular disease is a common complication of type 2 diabetes mellitus (T2DM), a major factor for disability and death. The current study shows that plasminogen activator inhibitor -1 (PAI-1) in T2DM, insulin resistance and vascular disease in the occurrence and development play a key role. This study approaches plasma PAI-1 levels in patients with type 2 diabetes mellitus, and the relevance of urine micro-albumin to understand PAI-1 in type 2 diabetes mellitus and its vascular complications in the pathogenesis of role.MethodsSelect from November 2008 to August 2009 at the Anshan Iron and Steel General Hospital inpatient wards and outpatient endocrine clinic meet inclusion criteria at the age of 33 years to 60 years of age with type 2 diabetes among 60 patients as research objects, (Diagnosis of diabetes based on 1999 WHO diagnostic criteria for diabetes mellitus),which came to hospital first and weren't recepted theropy. Exclusion criteria: liver, renal insufficiency, infectious disease, cerebrovascular disease, and pregnancy, breast-feeding patients were. Choose to age, sex, weight, blood pressure etc. and the study matched 30 cases of healthy people as control group. The experimental group according to presence or absence of microalbuminuria in type 2 diabetes mellitus is divided into microalbuminuria normal group (30 cases) and type 2 diabetes with microalbuminuria positive group (30 cases), under fasting venous blood taken with EDTA tube 2ml, specimens from the supernatant after centrifugation, placed in 80 degrees below zero refrigerator, detected altogether PAI-1. The control group with type 2 diabetes, plasma PAI-1 there is no difference, and then compare the group with type 2 diabetes, microalbuminuria normal group and microalbuminuria positive group PAI-1 values have no difference in application of its results SPSS11.0 statistical software to conduct T tests, multiple stepwise regression analysis, processing, and make the appropriate conclusions.Results1. General clinical data : matching the subsets of experiment group and control group by age, sex, blood pressure, there is no statistically significant difference(P>0.05), and comparing BMI between the subsets of experiment and control group, there is no statistically significant difference(P>0.05).2. Biochemical data: comparing FPG, HbA1c between experiment group and control group, there is statistacally significant difference(P<0.01), and between various sub-groups, there is no statistacally significant difference(P>0.05), blood lipid: the level of blood lipids in experiment group are more than the level of blood lipids in the control, and there is statistacally significant difference on the TC,TG,LDL-C(P<0.01,P<0.05,P<0.05), while there is no statistacally significant difference on the HDL-C(P>0.05). There is no statistacally significant difference between the various sub-groups in experiment group(P>0.05).FINS: comparing FINS between control group and microalbuminuria normal group in experiment group, there is no statistacally significant difference (P>0.05), comparing FINS between control group and microalbuminuria positive group in experiment groups, there is statistacally significant difference(P<0.05),comparing FINS between the various sub-groups in experiment group, there is statistacally significant difference(P<0.01).3. Insulin sensitivity HOMA-IR: the experimental group compared with the control group higher than that, there is statistically significant difference (P<0.05), the experimental group between the various sub-groups, there is no statistically significant difference (P> 0.05).4. Experimental index PAI-1: Microalbuminuria group fasting plasma PAI-1 levels is higher than the normal albuminuria group (P<0.01), microalbuminuria normal fasting plasma PAI-1 levels is higher than the control group (P<0.01).5. A simple correlation analysis: The fasting plasma PAI-1 as the dependent variable, a simple correlation analysis showed that (1), PAI-1 and urine micro-albumin, insulin resistance (HOMA-IR), FPG, HbA1c, BMI was positively related, r values were To 0.67,0.583,0.707,0.70,0.332 (P<0.01) (2), PAI-1 and TC, TG were positively related, r values were 0.31,0.213 (P<0.01,P <0.05).6. Multiple stepwise regression analysis : The fasting plasma PAI-1 as the dependent variable in order to Alb/cr, FPG, HbA1c, HOMA-IR, TC, TG, LDL-C, HDL-C, BMI as the independent variable, multiple regression analysis (factors that determine the level of filtering is set to 0.05) and found that Alb / cr, HbA1c finally enter the equation, thus affecting the level of fasting plasma PAI-1 most significant factors which can explain HbA1c fasting plasma PAI-1 concentration of 49.3%, Alb/cr can explain the changes in fasting plasma concentrations of PAI -1 28.9% (corrected R~2 values were 0.493,0.782, P <0.01).Conclusions1. Plasma PAI-1 concentration in patients with type 2diabetes mellitus increases, and it inceases greater in those patients type 2 diabetes mellitus with microalbuminuria.2. Plasma PAI-1 and urine microalbumin in patients with type 2 diabetes mellitus hade a positive correlation. It showed that PAI-1 may be one of the factors that occurred the vascular complications.